CompletedPHASE2, PHASE3NCT03974178
Fexinidazole in Human African Trypanosomiasis Due to T. b. Rhodesiense
Studying African trypanosomiasis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Drugs for Neglected Diseases
- Principal Investigator
- Enock Matovu, ProfMakerere University
- Intervention
- Fexinidazole(drug)
- Enrollment
- 45 enrolled
- Eligibility
- 6 years · All sexes
- Timeline
- 2019 – 2022
Study locations (2)
- Rumphi District Hospital, Rumphi, Malawi
- Lwala Hospital, Lwala, Kadeberamaido, Uganda
Collaborators
European and Developing Countries Clinical Trials Partnership (EDCTP)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03974178 on ClinicalTrials.govOther trials for African trypanosomiasis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07106385The Effectiveness of Repetitive Transcranial Magnetic Stimulation (rTMS) on Improving Sleep Quality in Adults Without Serious Mental IllnessThe University of Hong Kong
- ACTIVE NOT RECRUITINGNCT04565769Cognitive Function in Melanoma Patients Treated With Adjuvant Immune Checkpoint InhibitorsAarhus University Hospital
- RECRUITINGNCT01778504Studying Childhood-onset Behavioral, Psychiatric, and Developmental DisordersNational Institute of Mental Health (NIMH)